Tirzepatide is a dual GLP-1 and GIP receptor agonist developed by Eli Lilly and FDA-approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro). At My Concierge MD, tirzepatide therapy is prescribed and supervised by Dr. David Nazarian — a board-certified internal medicine physician trained at UCLA, the Sackler School of Medicine, and Huntington Memorial Hospital, a USC-affiliated teaching institution — within a comprehensive medical weight loss program in Beverly Hills.
Initially found Dr Nazarian for medical weight loss and then found out about all the regenerative and anti aging medicine services his medical clinic offers. They have one of the best IV exosomes and exosome therapy available. They have been able to help me overcome my fatigue as welll as lose weight safely and effectively. Their semaglutide injections for weight loss has really helped me lose weight and feel so much better.
The Science Behind Tirzepatide
Tirzepatide is the first medication to combine two distinct hormonal pathways involved in metabolic regulation. By acting on both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, it influences appetite signaling, glucose metabolism, gastric emptying, and energy balance through complementary mechanisms.
In Phase 3 clinical trials (the SURMOUNT program), patients on tirzepatide achieved an average weight loss of approximately 20 to 22 percent of body weight at the highest dose over 72 weeks — outcomes that exceeded those seen with single-pathway GLP-1 medications in head-to-head comparisons.
What Is Tirzepatide?
Tirzepatide is administered as a once-weekly subcutaneous injection and is marketed under two brand names:
- Mounjaro: FDA-approved for the treatment of adults with type 2 diabetes.
- Zepbound: FDA-approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
Treatment typically begins at 2.5 mg once weekly and is gradually titrated upward over several months, with maintenance doses ranging from 5 mg to 15 mg weekly based on individual response and tolerability.
Who Is a Candidate for Tirzepatide?
Candidacy for tirzepatide is determined through clinical evaluation. Patients who may be considered include:
- BMI Criteria: Adults with a BMI of 30 or higher, or BMI of 27 or higher with weight-related health conditions such as hypertension, type 2 diabetes, or dyslipidemia.
- Metabolic Considerations: Patients with type 2 diabetes, prediabetes, or metabolic syndrome who would benefit from dual GLP-1/GIP receptor activation.
- Prior Treatment History: Patients who have not achieved adequate results with lifestyle modification alone or with single-agent GLP-1 therapy.
- Health Status: Patients without contraindications who can commit to the structured follow-up required for safe long-term treatment.
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), severe gastrointestinal disease, or known hypersensitivity to the medication.
What to Expect During Treatment
Treatment begins with a comprehensive consultation that includes a review of medical history, current medications, contraindication screening, and discussion of treatment goals. Baseline laboratory studies are typically obtained before the first dose.
Dosing follows a structured titration schedule designed to minimize gastrointestinal side effects. The most common adverse effects include nausea, decreased appetite, diarrhea, constipation, and abdominal discomfort — most of which are mild to moderate and improve with continued therapy. Less common but more serious considerations include risk of pancreatitis, gallbladder disease, and acute kidney injury related to dehydration from gastrointestinal symptoms.
Patients are monitored closely throughout treatment with regular follow-up appointments to assess response, manage side effects, and adjust dosing as needed.
Frequently Asked Questions About Tirzepatide
-
Tirzepatide acts on two hormone receptors — GLP-1 and GIP — while semaglutide acts on GLP-1 only. In head-to-head clinical trials, tirzepatide produced greater average weight loss than semaglutide at comparable doses. Side effect profiles are similar between the two medications, though individual tolerability varies. Both can be discussed during a consultation as part of the practice’s broader medical weight loss program.
-
Tirzepatide is generally considered a long-term therapy. Most clinical evidence supports continued use for at least 72 weeks, with many patients remaining on maintenance therapy longer. Decisions about duration and potential discontinuation should be made in consultation with your physician based on individual goals, response, and overall metabolic health.
-
Coverage varies significantly by insurance plan and indication. Mounjaro is more commonly covered when prescribed for type 2 diabetes, while Zepbound coverage for obesity is expanding but still limited. Out-of-pocket and savings card options are available through Eli Lilly, and our team can discuss coverage and prior authorization during your consultation.
-
Weight regain after discontinuing tirzepatide is common, as the underlying physiology that drives appetite and metabolic regulation returns to its pre-treatment state. Clinical studies have shown that patients typically regain a significant portion of lost weight within one year of stopping the medication unless supported by ongoing lifestyle changes and continued metabolic management.
-
Tirzepatide is most effective when combined with nutrition guidance, structured exercise, and behavioral changes. Combining tirzepatide with other prescription weight loss medications is generally not recommended without specific clinical justification, but it is routinely paired with medically supervised weight loss support including nutrition counseling and metabolic optimization.
-
Most patients begin to notice appetite suppression within the first few weeks of treatment. Measurable weight loss typically begins within the first month and continues progressively as the dose is titrated upward. Maximum weight loss effects are generally seen between 12 and 18 months of consistent treatment combined with lifestyle support.
Why Choose My Concierge MD for Tirzepatide Therapy
- Physician-Led Care: Treatment is prescribed and managed directly by Dr. David Nazarian, a board-certified internal medicine physician with the institutional training and ABIM credentialing required for safe oversight of GLP-1/GIP therapy.
- Comprehensive Evaluation: Each candidate receives a full clinical assessment including medical history review, contraindication screening, baseline laboratory studies, and metabolic profiling before initiation.
- Close Follow-Up Monitoring: The concierge model allows for direct physician access, side-effect management, and dose adjustments throughout treatment rather than handoffs to a rotating team of providers.
- Integrated Weight Management: Tirzepatide is offered as part of a broader medical weight loss program that includes lifestyle, nutrition, and metabolic optimization rather than as a standalone prescription.
Schedule a Tirzepatide Consultation in Beverly Hills
To learn whether tirzepatide is appropriate for your weight loss goals, schedule a consultation with Dr. Nazarian at My Concierge MD in Beverly Hills. Each evaluation is conducted with the time, depth, and direct physician access that defines the concierge medicine model — serving patients across Beverly Hills and Greater Los Angeles.